Agreement - May 26, 2021
Zelluna Immunotherapy enters license agreement
The company has announced two exclusive license agreements with The University of Texas MD Anderson Cancer Center related to MAGE-A4 and VGLL1 targeting allogeneic “off-the-shelf” TCR-NK cell therapies for the treatment of various solid cancers. Under the agreements Zelluna will have exclusive rights from MD Anderson to use characterized TCRs targeting MAGE-A4 and VGLL1 for […]
Agreement - May 17, 2021
Iconovo extends agreement with Amneal
The expanded collaboration will include additional territories that lead to the announced potential for future annual royalty income more than doubling to USD 13.2 – 26.4 million. Iconovo and Amneal develop a generic Symbicort in the inhaler ICOres. The project is now entering the final phase, and Amneal has begun the set-up of commercial manufacturing […]
Agreement - May 5, 2021
Alligator Bioscience and BioArctic collaborate
The two companies have entered into a joint research agreement. Under the agreement, Alligator will employ its antibody generation technologies in collaboration with BioArctic to develop new product candidates, it states in a press release. “We are very pleased that BioArctic has recognized the power of Alligator’s proprietary phage display libraries which have been successfully […]
Agreement - April 20, 2021
BC Platforms enters new partnership
BC Platforms has announced a new strategic partnership with US-based company TripleBlind to help drive the development of privacy and intellectual property rights (IPR) preserving “federated AI” for its BCRQUEST.com Global Data Partner Network. The partnership will enhance BCP’s contribution to the Finnish-led PRIVASA (Privacy Preserving AI for Synthetic and Anonymous Health Data) consortium, which […]
Agreement - April 14, 2021
Hansa Biopharma collaborates with argenx
The companies have entered into a preclinical research collaboration agreement to evaluate the therapeutic potential of combining their two IgG-modulating technologies. The preclinical research collaboration is set up to explore the potential of combining imlifidase, Hansa’s IgG antibody-cleaving enzyme, and efgartigimod, argenx’s FcRn antagonist, which are both in development for indications known to be driven […]
Agreement - April 13, 2021
Lytix Biopharma in agreement with Arctic University of Norway
The company enters into an exclusive license agreement with the university for a class of new drug candidates and forms a strategic partnership with Aurelius Biotherapeutics. Lytix Biopharma, in collaboration with a research team at the Arctic University of Norway (UiT), has developed a new group of drug candidates, which can combat cancer cells through […]
